References for CEQUA® (cyclosporine ophthalmic solution) 0.09%

[a]**Study design:** Patient survey feedback was collected from dry eye disease patients who were nominally compensated for their time. Patients participating in the survey were supplied with a 5-day CEQUA sample along with their prescription. Participants completed 4 surveys: one at registration (prior to using CEQUA), and one at 1 month, 2 months, and 3 months.[1]

[b]The safety of CEQUA was evaluated in clinical trials that included 769 patients who received at least 1 dose of study treatment.[2]

[c]Instillation site pain included burning and stinging.

[d]The first time they tried CEQUA, 9 out of 10 patients reported no or mild discomfort after 3 minutes.[4]

References:

1. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
2. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.
3. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology*. 2019;126(9):1230-1237.
4. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol*. 2018;12:1921-1929.

PM-US-CQA-1868 06/2025